Breath Therapeutics GmbH
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Jan 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 18, 2027The maintenance fee for Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (BOS) (US 11,701,403) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 1 fee due Mar 5, 2027The maintenance fee for Cyclosporine Formulations for Use in the Prevention or Treatment of Pulmonary Chronic Graft Rejection (US 11,744,872) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 1 fee due Apr 20, 2027The maintenance fee for Pharmaceutical compositions comprising cyclosporin (US 9,161,963) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.
- 1 fee due Aug 6, 2027The maintenance fee for Inhalable compositions for use in the treatment of pulmonary diseases (US 11,890,376) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 24, 2026
- Nov 3 US 12,779,011 Cyclosporine Formulations for Use in the Prevention or Treatment of Pulmonary Chronic Graft Rejection
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,724,382 | Pharmaceutical compositions comprising cyclosporin In force · USPTO record | In force | USPTO record | |
| US 9,161,963 | Pharmaceutical compositions comprising cyclosporin In force · USPTO record | In force | USPTO record | |
| US 10,857,198 | Cyclosporine Formulations for Use in the Prevention or Treatment of Pulmonary Chronic Graft Rejection In force · High confidence | In force | High confidence | |
| US 11,744,872 | Cyclosporine Formulations for Use in the Prevention or Treatment of Pulmonary Chronic Graft Rejection In force · High confidence | In force | High confidence | |
| US 12,779,011 | Cyclosporine Formulations for Use in the Prevention or Treatment of Pulmonary Chronic Graft Rejection In force · High confidence | In force | High confidence | |
| US 11,701,403 | Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (BOS) In force · USPTO record | In force | USPTO record | |
| US 12,178,843 | Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (BOS) In force · USPTO record | In force | USPTO record | |
| US 11,484,566 | Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (BOS) In force · USPTO record | In force | USPTO record | |
| US 11,419,819 | Inhalable compositions for use in the treatment of pulmonary diseases In force · USPTO record | In force | USPTO record | |
| US 11,890,376 | Inhalable compositions for use in the treatment of pulmonary diseases In force · USPTO record | In force | USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 1 abandoned · 1 no status recorded